A key barrier to the development of vaccines that induce broadly neutralizing antibodies
(bnAbs) against human immunodeficiency virus (HIV) and other viruses of high antigenic …

Eliciting potent and broadly neutralizing antibodies (bnAbs) is a major goal in HIV-1 vaccine
development. Here, we describe how germline-targeting immunogen BG505 SOSIP …

The COVID-19 pandemic placed the field of vaccinology squarely at the center of global
consciousness, emphasizing the vital role of vaccines as transformative public health tools …

Adolescents are a growing population of people living with HIV. The period between
weaning and sexual debut presents a low-risk window for HIV acquisition, making early …

The eradication of the viral reservoir represents the major obstacle to the development of a
clinical cure for established HIV-1 infection. Here, we demonstrate that the administration of …

Broadly neutralizing antibodies (bnAbs) targeting the human immunodeficiency virus-1 (HIV-
1) have played a crucial role in elucidating and characterizing neutralization-sensitive sites …

Serum titers of SARS-CoV-2-neutralizing antibodies (nAbs) correlate well with protection
from symptomatic COVID-19 but decay rapidly in the months following vaccination or …

mRNA vaccine technology has proven to be a viable approach for effectively triggering
immune responses that protect against or limit viral infections and disease. In our study, we …

Broadly neutralizing antibodies (bNAbs) targeting the HIV-1 envelope glycoprotein (Env)
have the capacity to delay viral rebound when administered to people with HIV-1 (PWH) …

Abstract HIV-1 envelope glycoproteins (Envs) of most primary HIV-1 strains exist in closed
conformation and infrequently sample open states, limiting access to internal epitopes. Thus …